Loading
Ernexa Therapeutics Inc. Stock: price and insider trades · United States
US·Mcap US$5.3M
No insider purchase over the last 90 days. The latest was filed 17 Feb 2026.
Ernexa Therapeutics Inc.: what insiders have been doing
Every trade that managers of Ernexa Therapeutics Inc. disclose to SEC (Form 4) is tracked on this page. From 18 October 2025 to 18 October 2026, the disclosure feed for Ernexa Therapeutics Inc. logged 1 filing by 1 insider.
The flow runs one way only: 1 insider bought (1 purchase totalling €1.7M) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Cherington Charles filed the largest purchase, €1.7M, on 17 February 2026.
Compared with its exchange (5,458 companies, median 22 filings), a count of 1 filing is below the norm. Over the whole record (from 2021), the tally stands at 8 purchases and 2 sales.
The latest purchase dates back some time: it was published 243 days ago, on 17 February 2026.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
17
Thresholds
n/a
Buy Volume
€6M
8 ops. · all time
Sell Volume
€4M
2 ops. · all time
Who traded when
BuySaleCharles Cherington3 buys
Since the insiders bought
- +27.2%Entry US$9.00 · Close at T+90 US$11.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ernexa Therapeutics Inc. Strong Buy (bullish), based on 1 analysts. Average price target: US$30.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.53
Analyst consensus
1 analystsStrong buy
US$30.00Target US$30.00(+562%)US$30.00
Income statement
RevenueUS$5M
Gross profitUS$418.4k8% margin
EBITDA-US$13.8M-277% margin
Net income-US$14.1M0.0% margin
Valuation
PER (trailing)0.0x
P/Book0.6x
Beta2.56
Balance sheet & cash
Market capUS$5.3M
Total debtUS$490k
Free Cash Flow-US$7.1M
Debt / Equity6%
Profitability & ownership
ROE-2505.6%
ROA-81.2%
% insiders41.7%
% institutions10.2%
Last declaration on 17 February 2026
Declarations17 total
4,000,000 shares@ US$0.5046.4% of flowCommon StockSEC:0001104659-26-016680:0
Canonical exit: 11 May 2026 (T+90)
30 sharesCommon StockSEC:0001641172-25-018063:0
21,241,163 shares@ US$0.104653.6% of flowCommon StockSEC:0001104659-25-058644:0
Canonical exit: 7 Sept 2025 (T+90)
261,756 sharesCommon StockSEC:0001104659-25-045416:0
Canonical exit: 23 Dec 2024 (T+90)
3,768,397 shares@ US$0.104630.7% of flowCommon StockSEC:0001104659-25-032060:0
Canonical exit: 1 Jul 2025 (T+90)
261,756 sharesCommon StockSEC:0001104659-24-114222:0
Canonical exit: 27 Jan 2025 (T+90)
437 sharesCommon StockSEC:0001493152-24-025105:0
438 sharesCommon StockSEC:0001140361-23-031258:0
261,756 shares@ US$3.2869.3% of flowCommon StockSEC:0001140361-22-044639:0
Canonical exit: 2 Mar 2023 (T+90)
70,822 shares@ US$3.28100.0% of flowCommon StockSEC:0001140361-22-044631:0
Canonical exit: 2 Mar 2023 (T+90)
335,920 shares@ US$3.28100.0% of flowCommon StockSEC:0001062993-22-023351:0
Canonical exit: 2 Mar 2023 (T+90)
20,163 sharesCommon StockSEC:0001140361-22-034312:0
17,573 sharesCommon StockSEC:0001140361-22-024524:0
8,750 sharesCommon StockSEC:0001140361-22-023928:0
92 shares0Common StockSEC:0001140361-21-041286:0
75,000 shares@ US$16.0625100.0% of flowCommon StockSEC:0001062993-21-007818:0
200,000 shares@ US$15.7338100.0% of flowCommon StockSEC:0001140361-21-021772:0
17 of 17 declarations
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. is a company focused on developing innovative therapeutic treatments. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
